NEW YORK (AP) - Shares of drug developer Kadmon Holdings tumbled Wednesday after its initial public offering priced far below the company's estimates.
Kadmon said its offering of 6.25 million shares priced at $12 a share, raising $75 million in total. The company originally planned to sell 5.
Drug developer Kadmon skids following weak demand for IPO
Aucun commentaire:
Enregistrer un commentaire